Breast Neoplasms Clinical Trial
Official title:
Regional Anesthesia and Breast Cancer Recurrence
In this multi-center trial, Stage 1-3 patients having mastectomies or isolated lumpectomy with axillary node dissection will be randomly assigned to thoracic epidural or paravertebral anesthesia/analgesia, or to general anesthesia and morphine analgesia. Participants will be followed for up to 10 years to determine the rate of cancer recurrence or metastasis.
Surgery is the primary and most effective treatment of breast cancer, but residual disease in
the form of scattered micrometastases and tumor cells are usually unavoidable. Whether
minimal residual disease results in clinical metastases is a function of host defense and
tumor survival and growth. At least three perioperative factors shift the balance toward
progression of minimal residual disease:
1. Surgery per se depresses cell-mediated immunity, reduces concentrations of tumor-related
anti-angiogenic factors (e.g., angiostatin and endostatin), increases concentrations of
pro-angiogenic factors such as VEGF, and releases growth factors that promote local and
distant growth of malignant tissue.
2. Anesthesia impairs numerous immune functions, including those of neutrophils,
macrophages, dendritic cells, T-cell, and natural killer cells.
3. Opioid analgesics inhibit both cellular and humoral immune function in humans, increase
angiogenesis, and promote breast tumor growth in rodents.
However, regional analgesia attenuates or prevents each of these adverse effects by largely
preventing the neuroendocrine surgical stress response, eliminating or reducing the need for
general anesthesia, and minimizing opioid requirement. Animal studies indicate that regional
anesthesia and optimum postoperative analgesia independently reduce the metastatic burden in
animals inoculated with breast adenocarcinoma cells following surgery. Preliminary data in
cancer patients are also consistent: paravertebral analgesia for breast cancer surgery
reduced risk of recurrence or metastasis approximately four-fold (95% CI of estimated hazard
ratio is 0.71 - 0.06) during a 2.5 to 4-year follow-up period compared to opioid analgesia.
The investigators will thus test the hypothesis that recurrence after breast cancer surgery
is lower with regional anesthesia/analgesia than with general anesthesia and opioid
analgesia.
In this multi-center trial, Stage 1-3 patients having mastectomies will be randomly assigned
to thoracic epidural or paravertebral anesthesia/analgesia, or to general anesthesia and
opioid analgesia. As with all time-to-event trials, interim and final analyses are based on
the number of outcome events (recurrences in this case) rather than enrollment. The number of
patients required is just an estimate and varies based on actual recurrence rates which in
turn depend on patients' stage and grade, and ancillary treatments. There will be three
evenly spaced interim analyses and a final analysis at 351 recurrences. Confirming our
hypothesis will indicate that a minor modification to anesthetic management, one that can be
implemented with little risk or cost, will reduce the risk of cancer recurrence — a
complication that is often ultimately lethal.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05558917 -
Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery
|
N/A | |
Active, not recruiting |
NCT03664778 -
Abbreviated Breast MRI After Cancer Treatment
|
||
Recruiting |
NCT03144622 -
18F-FSPG PET/CT Imaging in Patients With Cancers
|
||
Completed |
NCT05452499 -
Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae
|
N/A | |
Active, not recruiting |
NCT04568902 -
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT02860585 -
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03698942 -
Delphinus SoftVue™ ROC Reader Study
|
||
Completed |
NCT00092950 -
Exercise in Women at Risk for Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02151071 -
The Breast Surgery EnLight and LightPath Imaging System Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT02934360 -
TR(ACE) Assay Clinical Specimen Study
|
N/A | |
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Completed |
NCT02931552 -
Nuevo Amanecer II: Translating a Stress Management Program for Latinas
|
N/A | |
Not yet recruiting |
NCT02876848 -
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
|
N/A | |
Recruiting |
NCT02547545 -
Breast Cancer Chemotherapy Risk Prediction Mathematical Model
|
N/A | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Completed |
NCT02303366 -
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
|
Phase 1 | |
Completed |
NCT02518477 -
Preventive Intervention Against Lymphedema After Breast Cancer Surgery
|
N/A |